Bal Pharma Ltd

Bal Pharma Ltd., a Bangalore-based pharmaceutical manufacturer and member of the Micro Laboratories Group, reported consolidated net profit of ₹1.78 crores for Q3 FY26 (October-December 2025), marking a dramatic 270.83% year-on-year surge from ₹0.48 crores in Q3 FY25. The micro-cap pharmaceutical company, with a market capitalisation of ₹121.00 crores, saw its stock surge 6.79% to ₹75.82 following the results announcement, though the shares remain 41.16% below their 52-week high of ₹128.86.

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 09 February 2026, providing investors with an up-to-date view of its performance and prospects.

Bal Pharma Ltd’s shares declined sharply to a fresh 52-week low of Rs.64 on 2 Feb 2026, marking a significant downturn in the stock’s performance over the past year. The stock’s fall reflects ongoing pressures on the company’s financial metrics and relative underperformance within the Pharmaceuticals & Biotechnology sector.

Bal Pharma Ltd’s shares declined to a fresh 52-week low of Rs.65.01 on 30 Jan 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed both its sector and the broader market, reflecting persistent pressures on its financial and operational metrics.

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 29 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Bal Pharma Ltd’s shares touched a fresh 52-week low of Rs.66 today, marking a significant decline amid sustained downward momentum. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on the company’s financial performance and valuation metrics.

Bal Pharma Ltd’s share price has declined to a fresh 52-week low of ₹67.15, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s shares are currently trading just 1.25% above this low, reflecting sustained pressure amid subdued financial performance and valuation concerns.

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Bal Pharma Ltd’s shares declined to a fresh 52-week low of Rs.67.15 on 30 Dec 2025, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects a sustained period of underperformance relative to the broader market and sector benchmarks.

Bal Pharma Ltd’s shares declined to a fresh 52-week low of Rs.67.15 today, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects persistent pressures on the company’s valuation amid subdued financial performance and sector-wide challenges.

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 25 December 2025, providing investors with the latest insights into the company’s performance and outlook.

Bal Pharma has reached a new 52-week low of Rs.70.2, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical company’s shares have underperformed both its sector and the broader market, reflecting ongoing pressures on its financial performance and valuation metrics.

Bal Pharma's shares reached a fresh 52-week low of Rs.70.2 today, marking a significant decline amid ongoing downward momentum. The stock has recorded losses over the past two sessions, reflecting persistent pressures within the Pharmaceuticals & Biotechnology sector.

Bal Pharma has experienced a revision in its market evaluation, reflecting a more cautious outlook driven by recent financial results, valuation considerations, and technical trends. This shift highlights the complexities facing the pharmaceutical company amid ongoing sector challenges and market pressures.

Bal Pharma's shares touched a fresh 52-week low of Rs.73.04 today, marking a significant milestone in the stock's ongoing downward trajectory. This new low reflects continued pressures on the company’s financial performance and market valuation within the Pharmaceuticals & Biotechnology sector.